JP2000509707A - 免疫原性複合体、その使用、製造法およびそれを含有するワクチン - Google Patents

免疫原性複合体、その使用、製造法およびそれを含有するワクチン

Info

Publication number: JP2000509707A
Authority: JP; Japan
Prior art keywords: protein; seq; salmonella; oligosaccharide; immunogenic
Prior art date: 1996-05-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP9539595A

Other languages

English (en)

Japanese (ja)

Inventor

ハンス、ビンズ

ジャン―フランソワ、アウー

ステファン、スベンソン

Original Assignee

ピエール、ファーブル、メディカマン

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-07

Filing date

1997-05-06

Publication date

2000-08-02

1997-05-06 Application filed by ピエール、ファーブル、メディカマン filed Critical ピエール、ファーブル、メディカマン

2000-08-02 Publication of JP2000509707A publication Critical patent/JP2000509707A/ja

Status Pending legal-status Critical Current

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 51
230000002163 immunogen Effects 0.000 title claims abstract description 47
238000004519 manufacturing process Methods 0.000 title claims abstract description 7
238000000034 method Methods 0.000 title claims description 34
150000002482 oligosaccharides Polymers 0.000 claims abstract description 78
150000004676 glycans Chemical class 0.000 claims abstract description 40
229920001282 polysaccharide Polymers 0.000 claims abstract description 40
239000005017 polysaccharide Substances 0.000 claims abstract description 40
241000894006 Bacteria Species 0.000 claims abstract description 34
102000014914 Carrier Proteins Human genes 0.000 claims abstract description 27
108010078791 Carrier Proteins Proteins 0.000 claims abstract description 25
239000012634 fragment Substances 0.000 claims abstract description 9
102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 6
108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 6
101710116435 Outer membrane protein Proteins 0.000 claims abstract description 6
241000194017 Streptococcus Species 0.000 claims abstract description 5
108090000623 proteins and genes Proteins 0.000 claims description 93
102000004169 proteins and genes Human genes 0.000 claims description 78
229920001542 oligosaccharide Polymers 0.000 claims description 74
239000002158 endotoxin Substances 0.000 claims description 35
229920006008 lipopolysaccharide Polymers 0.000 claims description 33
241000607142 Salmonella Species 0.000 claims description 28
239000000427 antigen Substances 0.000 claims description 28
108091007433 antigens Proteins 0.000 claims description 28
102000036639 antigens Human genes 0.000 claims description 28
239000012528 membrane Substances 0.000 claims description 19
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
230000008878 coupling Effects 0.000 claims description 11
238000010168 coupling process Methods 0.000 claims description 11
238000005859 coupling reaction Methods 0.000 claims description 11
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 10
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 10
SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 10
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 10
241000588747 Klebsiella pneumoniae Species 0.000 claims description 9
241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims description 9
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 8
230000005847 immunogenicity Effects 0.000 claims description 8
208000015181 infectious disease Diseases 0.000 claims description 8
241001465754 Metazoa Species 0.000 claims description 7
241000588748 Klebsiella Species 0.000 claims description 6
241000588653 Neisseria Species 0.000 claims description 6
241000282414 Homo sapiens Species 0.000 claims description 5
229930182830 galactose Natural products 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
241000606790 Haemophilus Species 0.000 claims description 4
230000000890 antigenic effect Effects 0.000 claims description 4
230000000717 retained effect Effects 0.000 claims description 4
241000588722 Escherichia Species 0.000 claims description 3
241000607768 Shigella Species 0.000 claims description 3
230000003213 activating effect Effects 0.000 claims description 3
GZCGUPFRVQAUEE-UHFFFAOYSA-N alpha-D-galactose Natural products OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 claims description 3
108091008324 binding proteins Proteins 0.000 claims description 2
235000018102 proteins Nutrition 0.000 description 71
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
239000000872 buffer Substances 0.000 description 21
235000001014 amino acid Nutrition 0.000 description 20
150000001413 amino acids Chemical class 0.000 description 20
235000000346 sugar Nutrition 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
239000007924 injection Substances 0.000 description 15
238000002347 injection Methods 0.000 description 15
241000699670 Mus sp. Species 0.000 description 14
238000005119 centrifugation Methods 0.000 description 13
BHATUINFZWUDIX-UHFFFAOYSA-N Zwittergent 3-14 Chemical compound CCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O BHATUINFZWUDIX-UHFFFAOYSA-N 0.000 description 12
239000000203 mixture Substances 0.000 description 12
238000000746 purification Methods 0.000 description 12
239000000243 solution Substances 0.000 description 12
201000008297 typhoid fever Diseases 0.000 description 11
239000013598 vector Substances 0.000 description 11
208000037386 Typhoid Diseases 0.000 description 10
210000003000 inclusion body Anatomy 0.000 description 10
238000011069 regeneration method Methods 0.000 description 10
238000003756 stirring Methods 0.000 description 10
230000001580 bacterial effect Effects 0.000 description 9
230000000694 effects Effects 0.000 description 9
230000008929 regeneration Effects 0.000 description 9
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 8
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 8
239000002671 adjuvant Substances 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
239000012141 concentrate Substances 0.000 description 8
238000000502 dialysis Methods 0.000 description 8
230000003053 immunization Effects 0.000 description 8
238000002649 immunization Methods 0.000 description 8
229940045505 klebsiella pneumoniae Drugs 0.000 description 8
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
108010079246 OMPA outer membrane proteins Proteins 0.000 description 7
239000000463 material Substances 0.000 description 7
239000002609 medium Substances 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
230000004044 response Effects 0.000 description 7
238000002255 vaccination Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
108010052285 Membrane Proteins Proteins 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 6
239000000284 extract Substances 0.000 description 6
230000003287 optical effect Effects 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
238000010367 cloning Methods 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
229960003983 diphtheria toxoid Drugs 0.000 description 5
239000008188 pellet Substances 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
239000003053 toxin Substances 0.000 description 5
231100000765 toxin Toxicity 0.000 description 5
108700012359 toxins Proteins 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
229940041514 candida albicans extract Drugs 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000004925 denaturation Methods 0.000 description 4
230000036425 denaturation Effects 0.000 description 4
206010013023 diphtheria Diseases 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000012138 yeast extract Substances 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
108010060123 Conjugate Vaccines Proteins 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
241000233866 Fungi Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
101100081697 Klebsiella pneumoniae ompA gene Proteins 0.000 description 3
102000018697 Membrane Proteins Human genes 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 3
230000003321 amplification Effects 0.000 description 3
150000001450 anions Chemical class 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
238000011210 chromatographic step Methods 0.000 description 3
239000007979 citrate buffer Substances 0.000 description 3
229940031670 conjugate vaccine Drugs 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229960000789 guanidine hydrochloride Drugs 0.000 description 3
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
230000000521 hyperimmunizing effect Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
229940031551 inactivated vaccine Drugs 0.000 description 3
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
244000052769 pathogen Species 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
239000000047 product Substances 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
241000894007 species Species 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
238000000108 ultra-filtration Methods 0.000 description 3
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000192125 Firmicutes Species 0.000 description 2
108091006027 G proteins Proteins 0.000 description 2
102000030782 GTP binding Human genes 0.000 description 2
108091000058 GTP-Binding Proteins 0.000 description 2
101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
101150065207 P40 gene Proteins 0.000 description 2
206010039438 Salmonella Infections Diseases 0.000 description 2
241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229940124929 TYPHIM Vi Drugs 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
241001467018 Typhis Species 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000002096 anti-tetanic effect Effects 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
229960001212 bacterial vaccine Drugs 0.000 description 2
239000007640 basal medium Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
238000005277 cation exchange chromatography Methods 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
229960002798 cetrimide Drugs 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
238000013461 design Methods 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
108010091000 endorhamnosidase Proteins 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
229930027917 kanamycin Natural products 0.000 description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
229960000318 kanamycin Drugs 0.000 description 2
229930182823 kanamycin A Natural products 0.000 description 2
IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
150000002772 monosaccharides Chemical class 0.000 description 2
102000045222 parkin Human genes 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000010405 reoxidation reaction Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
206010039447 salmonellosis Diseases 0.000 description 2
230000007017 scission Effects 0.000 description 2
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
238000000527 sonication Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
PLVPPLCLBIEYEA-WAYWQWQTSA-N (z)-3-(1h-indol-3-yl)prop-2-enoic acid Chemical compound C1=CC=C2C(\C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-WAYWQWQTSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
108010071023 Bacterial Outer Membrane Proteins Proteins 0.000 description 1
239000002028 Biomass Substances 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000193449 Clostridium tetani Species 0.000 description 1
241001337994 Cryptococcus <scale insect> Species 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000004232 Enteritis Diseases 0.000 description 1
241000588914 Enterobacter Species 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
241000239218 Limulus Species 0.000 description 1
241001149698 Lipomyces Species 0.000 description 1
101710175243 Major antigen Proteins 0.000 description 1
101710164702 Major outer membrane protein Proteins 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
208000034762 Meningococcal Infections Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
241000207836 Olea <angiosperm> Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000845082 Panama Species 0.000 description 1
206010033971 Paratyphoid fever Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
241000522522 Salmonella enterica subsp. enterica serovar Abortusovis Species 0.000 description 1
241001148137 Salmonella enterica subsp. enterica serovar Panama Species 0.000 description 1
241000607149 Salmonella sp. Species 0.000 description 1
244000292604 Salvia columbariae Species 0.000 description 1
235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
235000001498 Salvia hispanica Nutrition 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
241000607715 Serratia marcescens Species 0.000 description 1
241000607764 Shigella dysenteriae Species 0.000 description 1
101001060868 Strawberry mild yellow edge-associated virus Helicase Proteins 0.000 description 1
229940124840 Streptococcal vaccine Drugs 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
241001475173 Tarsocera Species 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
208000035472 Zoonoses Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
230000032683 aging Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
235000012501 ammonium carbonate Nutrition 0.000 description 1
UOWSQRLVFRNTMV-UHFFFAOYSA-N aniline;isothiocyanic acid Chemical compound N=C=S.NC1=CC=CC=C1 UOWSQRLVFRNTMV-UHFFFAOYSA-N 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
235000014167 chia Nutrition 0.000 description 1
239000004020 conductor Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000009295 crossflow filtration Methods 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000000385 dialysis solution Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000003500 gene array Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
208000021760 high fever Diseases 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000006054 immunological memory Effects 0.000 description 1
PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
125000001905 inorganic group Chemical group 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
238000009434 installation Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
229940124590 live attenuated vaccine Drugs 0.000 description 1
229940023012 live-attenuated vaccine Drugs 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005374 membrane filtration Methods 0.000 description 1
230000003446 memory effect Effects 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940126578 oral vaccine Drugs 0.000 description 1
229960005030 other vaccine in atc Drugs 0.000 description 1
230000007170 pathology Effects 0.000 description 1
108010091718 peptide L Proteins 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229940031937 polysaccharide vaccine Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
229940007046 shigella dysenteriae Drugs 0.000 description 1
229910001961 silver nitrate Inorganic materials 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
229940031626 subunit vaccine Drugs 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009182 swimming Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
150000004044 tetrasaccharides Chemical class 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
239000007160 ty medium Substances 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000001018 virulence Effects 0.000 description 1
229940104152 vivotif Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
206010048282 zoonosis Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

JP9539595A 1996-05-07 1997-05-06 免疫原性複合体、その使用、製造法およびそれを含有するワクチン Pending JP2000509707A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR96/05692		1996-05-07
FR9605692A FR2748476B1 (fr)	1996-05-07	1996-05-07	Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant
PCT/FR1997/000800 WO1997041888A1 (fr)	1996-05-07	1997-05-06	Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant

Publications (1)

Publication Number	Publication Date
JP2000509707A true JP2000509707A (ja)	2000-08-02

Family

ID=9491907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP9539595A Pending JP2000509707A (ja)	1996-05-07	1997-05-06	免疫原性複合体、その使用、製造法およびそれを含有するワクチン

Country Status (9)

Country	Link
EP (1)	EP0914152A1 (fr)
JP (1)	JP2000509707A (fr)
CN (1)	CN1221348A (fr)
AU (1)	AU733845B2 (fr)
BR (1)	BR9708979A (fr)
CA (1)	CA2254084A1 (fr)
FR (1)	FR2748476B1 (fr)
NZ (1)	NZ332809A (fr)
WO (1)	WO1997041888A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009523736A (ja) *	2006-01-13	2009-06-25	バクスター・インターナショナル・インコーポレイテッド	ポリサッカライドを精製する方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2776521B1 (fr) *	1998-03-27	2000-12-15	Pf Medicament	Utilisation de conjugues p40 actifs par voie nasale
FR2785542B1 (fr) *	1998-11-06	2001-02-09	Pf Medicament	UTILISATION D'UNE PROTEINE OmpA D'ENTEROBACTERIE, POUR LE CIBLAGE SPECIFIQUE D'UNE SUBSTANCE BIOLOGIQUEMENT ACTIVE QUI LUI EST ASSOCIEE VERS LES CELLULES PRESENTATRICES D'ANTIGENES TELLES QUE LES CELLULES DENDRITIQUES HUMAINES
US6146902A (en) *	1998-12-29	2000-11-14	Aventis Pasteur, Inc.	Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
FR2789588B1 (fr) *	1999-02-17	2001-05-04	Pf Medicament	Utilisation d'une proteine ompa d'enterobacterie associee a un antigene dans une composition pharmaceutique destinee a generer ou accroitre une reponse cytotoxique antivirale, antiparasitaire ou antitumorale
FR2789902A1 (fr) *	1999-02-24	2000-08-25	Pf Medicament	PROTEINE OmpA DE KLEBSIELLA PNEUMONIAE ASSOCIEE A LA CHAINE BETA DE L'HORMONE hCG OU A UN COMPOSE IMPLIQUE DANS LA PROLIFERATION DE CELLULES TUMORALES OU DANS LA FERTILITE, UTILE DANS UNE COMPOSITION PHARMACEUTIQUE
FR2790959B1 (fr) *	1999-03-15	2003-06-27	Pf Medicament	Utilisation de fractions membranaires bacteriennes a effet adjuvant, leurs procedes de preparation et composition pharmaceutique les contenant
FR2828106A1 (fr) *	2001-08-02	2003-02-07	Pf Medicament	Utilisation d'une omp d'enterobacterie de faible masse moleculaire comme porteur et/ou adjuvant
CN107184972B (zh) *	2017-06-20	2020-12-01	康希诺生物股份公司	一种结核杆菌OS-tb寡糖缀合物及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1331355C (fr) *	1986-04-21	1994-08-09	Bioenterprises Pty. Ltd	Immunopotentialisation
FR2682388B1 (fr) *	1991-10-10	1995-06-09	Pasteur Merieux Serums Vacc	Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
US6153406A (en) *	1993-07-23	2000-11-28	North American Vaccine, Inc.	Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
FR2718452B1 (fr) *	1994-04-06	1996-06-28	Pf Medicament	Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
FR2726472B1 (fr) *	1994-11-07	1997-01-31	Pf Medicament	Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
FR2726471B1 (fr) *	1994-11-07	1997-01-31	Pf Medicament	Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins

1996
- 1996-05-07 FR FR9605692A patent/FR2748476B1/fr not_active Expired - Fee Related
1997
- 1997-05-06 CA CA002254084A patent/CA2254084A1/fr not_active Abandoned
- 1997-05-06 JP JP9539595A patent/JP2000509707A/ja active Pending
- 1997-05-06 AU AU29019/97A patent/AU733845B2/en not_active Ceased
- 1997-05-06 EP EP97923139A patent/EP0914152A1/fr not_active Withdrawn
- 1997-05-06 BR BR9708979A patent/BR9708979A/pt not_active Application Discontinuation
- 1997-05-06 CN CN97195397A patent/CN1221348A/zh active Pending
- 1997-05-06 NZ NZ332809A patent/NZ332809A/xx unknown
- 1997-05-06 WO PCT/FR1997/000800 patent/WO1997041888A1/fr not_active Ceased

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009523736A (ja) *	2006-01-13	2009-06-25	バクスター・インターナショナル・インコーポレイテッド	ポリサッカライドを精製する方法

Also Published As

Publication number	Publication date
EP0914152A1 (fr)	1999-05-12
NZ332809A (en)	2000-05-26
FR2748476A1 (fr)	1997-11-14
WO1997041888A1 (fr)	1997-11-13
CN1221348A (zh)	1999-06-30
AU733845B2 (en)	2001-05-31
FR2748476B1 (fr)	1998-08-14
CA2254084A1 (fr)	1997-11-13
BR9708979A (pt)	1999-08-03
AU2901997A (en)	1997-11-26

Publication	Publication Date	Title
TWI748810B (zh)	2021-12-01	包含結合之莢膜醣抗原的免疫原組合物及其用途
TWI720448B (zh)	2021-03-01	包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
CN104873965B (zh)	2018-09-11	包含肺炎链球菌荚膜多糖缀合物的疫苗
JP6093302B2 (ja)	2017-03-08	免疫原性組成物
TWI751513B (zh)	2022-01-01	E. coli O-抗原多醣生物結合物、其製備方法及其使用方法
KR102049825B1 (ko)	2019-12-03	스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
TWI487534B (zh)	2015-06-11	疫苗
TWI771663B (zh)	2022-07-21	E. coli O-抗原多醣生物結合物之製備方法、其組合物及其使用方法
TW201946650A (zh)	2019-12-16	針對腹內感染之疫苗
JP2023539943A (ja)	2023-09-20	多価ワクチン組成物及びその使用
CN101107010A (zh)	2008-01-16	经修饰的链球菌多糖及其用途
JP2000509707A (ja)	2000-08-02	免疫原性複合体、その使用、製造法およびそれを含有するワクチン
JP2022546763A5 (fr)	2023-08-01
JP2018522978A (ja)	2018-08-16	免疫原性組成物
US20030068324A1 (en)	2003-04-10	Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
JP2025538222A (ja)	2025-11-26	多価ワクチン組成物およびその使用
JP2016029103A (ja)	2016-03-03	免疫原性組成物
WO2025172892A1 (fr)	2025-08-21	Protéines modifiées et méthodes
PL229194B1 (pl)	2018-06-29	Neoglikokoniugat oligocukru Escherichia coli R1 LOS i toksoidu Clostridium difficile oraz jego zastosowanie w szczepionkach przeciwbakteryjnych
Cuello et al.	2005	Polysaccharide of meningococcal group C conjugated to different quantities of outer membrane vesicle from Neisseria meningitidis serogroup B

JP2000509707A - 免疫原性複合体、その使用、製造法およびそれを含有するワクチン - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=9491907

Family Applications (1)

Country Status (9)

Cited By (1)

Families Citing this family (8)

Family Cites Families (6)

Cited By (1)

Also Published As

Similar Documents